AbbVie has agreed to buy privately held biotechnology company Nimble Therapeutics ... AbbVie on Friday said the deal adds Nimble's lead asset, an investigational oral peptide in preclinical ...
AbbVie is paying $200 million to snap up Nimble Therapeutics, a Roche spinout working to develop oral peptide treatments in the autoimmune space. | AbbVie is paying $200 million to snap up Nimble ...
In a study published in Nature Methods, a research group developed a highly sensitive proteomics method called ...
Peptides are making waves in the bodybuilding world. Not only do they seem to have a better safety profile than SARMs and don ...